XSHG
603858
Market cap2.30bUSD
Oct 09, Last price
14.81CNY
1D
1.44%
1Q
-4.39%
Jan 2017
-79.80%
IPO
-78.25%
Name
Shandong Buchang Pharmaceuticals Co Ltd
Chart & performance
P/E
43.29
P/S
1.33
EPS
0.34
Div yield, %
2.67%
Shrs. gr., 5y
-0.92%
Rev. gr., 5y
-5.98%
Revenues
11.76b
+6.88%
Net income
361m
P
CFO
1.17b
+24.46%
Dividend
Aug 06, 20260.18 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shandong Buchang Pharmaceuticals Co., Ltd. is actively involved in China's pharmaceutical sector, specializing in the innovation, production, and distribution of medicinal products. The company provides a diverse range of treatments addressing various health conditions, including cardiovascular, cerebrovascular, urinary, digestive, and respiratory disorders, alongside gynecological problems and diabetes. Founded in 1993, this enterprise maintains its headquarters in Heze, China. Notably, it once operated as a subsidiary of Shanghai Zhangjiang (Group) Co., Ltd.
Key people
Buchang Zhao
Lifetime Honorary Chairman of the Board · since 2023
Chao Zhao
President · since 2025
Chao Zhao
President
Xiaogang Zhao
Chief Financial Officer · since 2025
Baocai Wang
Vice President · since 2025
Yimin Wang
Vice Chairman of the Board, Executive Vice President · since 2017
Xin Wang
Secretary of the Board, Director · since 2025
Yalin Lei
Director · since 2025
Minggeng Wang
Director · since 2025
Bing Wu
Staff Elected Director · since 2025
Renhui Xue
Vice President, Director · since 2012
Tao Zhao
Executive Officer, Chairman of the Boar
Tao Zhao
Chairman of the Board · since 2001
Jing Zhao
Vice Chairman of the Board · since 2017
Zhanming Chen
Independent Director · since 2025
Independent Director · since 2024
Independent Director · since 2025
Hao Wang
Independent Director · since 2024
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||